American Journal of Kidney Diseases
Volume 54, Issue 1 , Pages 159-164 , July 2009

A Forgotten Cause of Kidney Injury in Chronic Myelomonocytic Leukemia

  • Tejas V. Patel, MD, MPH

      Affiliations

    • Renal Division, Brigham and Women's Hospital, Boston, MA
    • ,
  • Helmut G. Rennke, MD

      Affiliations

    • Department of Pathology, Brigham and Women's Hospital, Boston, MA
    • ,
  • J. Mark Sloan, MD

      Affiliations

    • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA
    • ,
  • Daniel J. DeAngelo, MD, PhD

      Affiliations

    • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA
    • ,
  • David M. Charytan, MD, MSc

      Affiliations

    • Renal Division, Brigham and Women's Hospital, Boston, MA
    • Corresponding Author InformationAddress correspondence to David M. Charytan, MD, MSc, Renal Division, Center for Clinical Biometrics, Brigham and Women's Hospital, 1620 Tremont St, Boston, MA 02120

Received 25 June 2008 ,Accepted 3 November 2008.

References 

  1. Perazella MA, Eisen RN, Frederick WG, Brown E. Renal failure and severe hypokalemia associated with acute myelomonocytic leukemia. Am J Kidney Dis. 1993;22:462–467
  2. Humphreys BD, Sharman JP, Henderson JM, et al. Gemcitabine-associated thrombotic microangiopathy. Cancer. 2004;100:2664–2670
  3. Onida F, Kantarjian HM, Smith TL, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: A retrospective analysis of 213 patients. Blood. 2002;99:840–849
  4. Stark AN, Thorogood J, Head C, Roberts BE, Scott CS. Prognostic factors and survival in chronic myelomonocytic leukaemia (CMML). Br J Cancer. 1987;56:59–63
  5. Robinson GT, Sundaram KR, Dilly SA, Bevan DH, Andrews PA. Renal failure in a patient with chronic myelomonocytic leukaemia. Nephrol Dial Transplant. 1997;12:1500–1502
  6. Morschhauser F, Wattel E, Pagniez D, et al. Glomerular injury in chronic myelomonocytic leukemia. Leuk Lymphoma. 1995;18:479–483
  7. Osserman EF, Lawlor DP. Serum and urinary lysozyme (muramidase) in monocytic and monomyelocytic leukemia. J Exp Med. 1966;124:921–952
  8. Saitoh T, Murakami H, Uchiumi H, et al. Myelodysplastic syndromes with nephrotic syndrome. Am J Hematol. 1999;60:200–204
  9. Mok CC, Tam SC, Kwong YL. Pseudonephrotic syndrome caused by lysozymuria. Ann Intern Med. 1994;121:818
  10. Thomson M, de Arriba G, Ordi J, Oliva H, Hernando L. Acute myelogenous leukemia treated with daunomycin associated with nephrotic syndrome. Nephron. 1989;51:261–264
  11. Morino N, Nojima Y, Mimura T, et al. Nephrotic syndrome developed in a patient with acute promyelocytic leukemia treated with daunomycin. Nephron. 1995;70:374–375
  12. Aguado MJ, Garcia de Bustos J, Ojeda E, Quevedo E, Foncillas MA, Hernandez Navarro F. Proteinuria caused by lysozymuria mimics nephrotic syndrome. Nephron. 2000;86:183
  13. Fleming A. On a remarkable bacteriolytic element found in tissues and secretions. Proc R Soc London. 1922;93:306–317
  14. Sussman M, Asscher AW, Jenkins JA. The intrarenal distribution of lysozyme (muramidase). Invest Urol. 1968;6:148–152
  15. Muggia FM, Heinemann HO, Farhangi M, Osserman EF. Lysozymuria and renal tubular dysfunction in monocytic and myelomonocytic leukemia. Am J Med. 1969;47:351–366
  16. Rosenthal DS, Maglio R, Moloney WC. Muramidasuria and hyperkaluria in the chloroleukemic rat. Proc Soc Exp Biol Med. 1972;141:499–500
  17. Picken MM, Shen S. Immunoglobulin light chains and the kidney: An overview. Ultrastruct Pathol. 1994;18:105–112
  18. Humes HD, Hunt DA, White MD. Direct toxic effect of the radiocontrast agent diatrizoate on renal proximal tubule cells. Am J Physiol. 1987;252:F246–F255
  19. Bernard A, Amor AO, Viau C, Lauwerys R. The renal uptake of proteins: A nonselective process in conscious rats. Kidney Int. 1988;34:175–185
  20. Online Medelian Inheritance in Man for Lysozyme. http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=153450Accessed August 27, 2008
  21. Yazaki M, Farrell SA, Benson MD. A novel lysozyme mutation Phe57Ile associated with hereditary renal amyloidosis. Kidney Int. 2003;63:1652–1657
  22. Pruzanski W, Platts ME. Serum and urinary proteins, lysozyme (muramidase), and renal dysfunction in mono- and myelomonocytic leukemia. J Clin Invest. 1970;49:1694–1708
  23. Levinson SS, Elin RJ, Yam L. Light chain proteinuria and lysozymuria in a patient with acute monocytic leukemia. Clin Chem. 2002;48:1131–1132
  24. Harrison JF, Parker RW, De Silva KL. Lysozymuria and acute disorders of renal function. J Clin Pathol. 1973;26:278–284
  25. Studdy PR, Lapworth R, Bird R. Angiotensin-converting enzyme and its clinical significance—A review. J Clin Pathol. 1983;36:938–947
  26. Tomita H, Sato S, Matsuda R, et al. Serum lysozyme levels and clinical features of sarcoidosis. Lung. 1999;177:161–167
  27. Aribi A, Borthakur G, Ravandi F, et al. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer. 2007;109:713–717
  28. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007;109:52–57

 Originally published online as doi: 10.1053/j.ajkd.2008.11.013 on January 30, 2009.

 Because an author of this manuscript is an editor for AJKD, the peer-review and decision-making processes were handled entirely by an Associate Editor (Jan Weening, MD, Tergooiziekenhuizen) who served as Acting Editor-in-Chief. Details of the journal's procedures for potential editor conflicts are given in the Editorial Policies section of the AJKD website.

PII: S0272-6386(08)01689-2

doi: 10.1053/j.ajkd.2008.11.013

American Journal of Kidney Diseases
Volume 54, Issue 1 , Pages 159-164 , July 2009

Article Tools

* Image Usage & Resolution